Bibliography
- EURORDIS website. Available from: www.eurordis.org
- European Medicines Agency website. Available from: www.ema.europa.eu
- Food and Drug Administration website. Available from: www.fda.gov/ForIndustry/DevelopingProductsfor RareDiseasesConditions/default.htm
- Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012;7:74
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85
- Remnant J, Cole J. Measuring the return from pharmaceutical innovation 2012: is R&D earning its investment? The Deloitte Centre for Health Solutions; 2012
- Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. Biosocieties 2011;6:34-50
- Reuters. GlaxoSmithKline boss says new drugs can be cheaper. Available from: http://www.reuters.com/article/2013/03/14/us-glaxosmithkline-prices-idUSBRE92D0RM20130314
- Hall AK. The price of value. Eur Biopharm Rev 2013;80-3
- Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012;17(13/14):660-4
- Eichler H-G, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012;91(3):426-37
- Dooms M, Pincé H, Simoens S. Do we need authorized orphan drugs when compounded medications are available? J Clin Pharm Ther 2013;38(1):1-2
- Rare Diseases: challenges and Opportunities for Social Entrepreneurs, Edited by Nicolas Sireau, Greenleaf. 2013. Available from: http://www.amazon.co.uk/Rare-Diseases-Challenges-Opportunities-Entrepreneurs/dp/1906093520/ref=sr_1_1?ie=UTF8&qid=1367920851&sr=8-1&keywords=rare+diseases